Pembrolizumab increases level of the patomorfologichesky full answer at patients with the threefold negative cancer of a mammary gland (TNCMG) at application in a combination with chemotherapy in a neoadjyuvantny mode

30.09.2019 – Company presented to MSD results of the research KEYNOTE-522 in which pembrolizumab it was applied in a neoadjyuvantnom/adjyuvantny mode at patients with early stages of the threefold negative cancer mammary gland (TNCMG)...